Harrow, Inc. (HROW), a Nashville-based eyecare pharmaceutical company, carries a strongly bullish analyst posture, though the individual stock price targets are unusually spread out. The targets reviewed include $60 from Lake Street, $60 from B. Riley Securities, $63 from BTIG, $62 from Ladenburg Thalmann, $70 from H.C. Wainwright, $88 from Cantor Fitzgerald, and $45 from Leerink Partners, with a roughly $59 target from Craig-Hallum. The arithmetic mean of these values is approximately $63, which is the central target used throughout this article.
That spread — roughly $45 to $88 — is wide and signals genuine disagreement. Bulls anchored to the high end (Cantor Fitzgerald, H.C. Wainwright) emphasize the rapid expansion of the branded ophthalmic franchise. Analysts near the low end reflect caution after a first half in which the company missed profitability expectations and slashed its full-year adjusted EBITDA outlook. Several firms have trimmed targets: B. Riley lowered its target from $65 to $60 and Ladenburg from $66 to $62, while Cantor Fitzgerald reduced its target to $88. Even the lowest target, however, sits well above the current share price.
Harrow closed at $27.47 on November 9, 2026, and rallied roughly 16% in after-hours trading to about $32 after reporting third-quarter results. From the $27.47 close, reaching the $63 central target requires a gain of roughly 130%; even measured from the post-earnings level, the move approaches 100%. By any standard, this is a very large required advance.
The path would depend on sustaining the branded-product acceleration into 2027. Third-quarter revenue reached a record $99.3 million, up 39% year over year, with branded revenue up 62% to $83.5 million — about 84% of the total. VEVYE (cyclosporine for dry eye disease) set a record, and TRIESENCE posted its first $10 million-plus quarter. Management reaffirmed full-year 2026 revenue guidance of $350 million to $365 million. The critical question is whether this top-line momentum translates into durable profitability, given the company is still loss-making on a trailing twelve-month basis.
The most concrete support is the branded portfolio's momentum. VEVYE's revenue growth, TRIESENCE's record quarter, and the October 2026 acquisition of TYRVAYA — the only FDA-approved nasal spray for dry eye disease — give management multiple levers, with TYRVAYA expected to contribute more than $30 million in 2027. The July 2026 launch of BYOOVIZ, a ranibizumab biosimilar, and a planned 2027 launch of OPUVIZ (an aflibercept biosimilar) extend the pipeline. GAAP net income turned positive in the third quarter at $9.8 million, versus a $17.3 million loss in the prior quarter. If branded growth continues and margins improve, the valuation could re-rate materially higher from a price-to-sales ratio around 4.
Profitability remains the central obstacle. Full-year 2026 adjusted EBITDA guidance was cut to "greater than $40 million," less than half the original $80 million to $100 million range, reflecting higher spending and first-half shortfalls. The company remains unprofitable on a trailing twelve-month basis, and its compounding segment continues to decline. Short interest near 20% of shares outstanding signals meaningful skepticism, and further EBITDA disappointments, slower-than-expected TYRVAYA adoption, or reimbursement friction could keep the multiple compressed. Insider selling and analyst target cuts through 2026 add to the caution.
The 52-week range of roughly $25.76 to $54.85 frames the technical picture. The $63 target sits about 15% above the 52-week high, meaning it would require a decisive breakout to new highs. The $25.76 low is the key support level below the market, while the 50-day and 200-day moving averages (near $31 and $38) mark nearer-term resistance zones the stock must reclaim first. Harrow has traded below both averages after a multi-month slide, so the technical structure currently favors caution over momentum.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms differ in their timing assumptions. Investors should watch fourth-quarter 2026 results and whether management meets its "strongest quarter" guidance, the ramp of TYRVAYA and BYOOVIZ, progress toward the reaffirmed $350 million to $365 million revenue range, and any recovery in adjusted EBITDA toward the $40 million-plus target. Additional analyst revisions — up or down — and changes in the elevated short interest will also shape how credible the $63 objective looks over time.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual chart review alone. Because signals update as data evolves, they can serve as a complementary tool alongside fundamental research when evaluating a volatile name like Harrow. Traders looking for a systematic way to track shifting momentum may find the signals a useful addition to their workflow.
Can Harrow stock reach $63? The arithmetic mean of roughly eight analyst targets sits near that level, but the range is wide — from $45 to $88 — and the required move is very large, roughly 100% to 130% depending on the reference price. The bull case rests on accelerating branded revenue, a record third quarter, and a growing pipeline of dry-eye and biosimilar products. The bear case centers on slashed EBITDA guidance, persistent losses, and heavy short interest. Reaching $63 would require both continued top-line execution and a durable turn toward profitability that re-rates the stock above its 52-week high. That outcome is possible but far from assured, and investors should watch the fourth quarter, TYRVAYA's ramp, and analyst revisions closely before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
| Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
|---|---|---|---|---|
| HROW | 100% | +10.52% | ||
| AQST - HROW | 34% Loosely correlated | -0.56% | ||
| AMRX - HROW | 32% Poorly correlated | +0.47% | ||
| AYTU - HROW | 28% Poorly correlated | +1.12% | ||
| RMTI - HROW | 27% Poorly correlated | -2.79% | ||
| TEVA - HROW | 27% Poorly correlated | -1.33% | ||
More | ||||
| Ticker / NAME | Correlation To HROW | 1D Price Change % |
|---|---|---|
| HROW | 100% | +10.52% |
| Pharmaceuticals: Generic industry (81 stocks) | 19% Poorly correlated | -0.76% |